Phase 3 Refractory Diffuse Large B-Cell Lymphoma Clinical Trials
3 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–3 of 3 trials
Recruiting
Phase 3
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hutchmed240 enrolled41 locationsNCT07409428
Recruiting
Phase 3
A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma
Recurrent and Refractory Diffuse Large B-cell Lymphoma
Chengdu Zenitar Biomedical Technology Co., Ltd390 enrolled1 locationNCT07011056
Recruiting
Phase 3
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
BeBetter Med Inc416 enrolled1 locationNCT06792253